Printer Friendly

Invitrogen Corporation Expands Cellular Assay Capabilities, To Acquire Sentigen Holding Corp.; Proprietary Tango(TM) and Cell Division Arrest Technologies Complement Invitrogen's Broad Assay Technology Platform.

CARLSBAD, Calif. -- Invitrogen Corporation (Nasdaq:IVGN), a global leader in life sciences, and Sentigen Holding Corp. (Nasdaq:SGHL) today announced that they had entered into a definitive merger agreement under which Invitrogen will acquire New Jersey-based Sentigen in a cash transaction at a price of $3.37 per share, or approximately $25.9 million for all shares currently issued and outstanding. As of June 30, 2006, Sentigen had cash and cash investments on its books valued at approximately $11.7 million and debt of $0.8 million.

Sentigen's proprietary Tango(TM) Assay System and division arrested Assay Ready Cells(TM) will bolster Invitrogen's leading position in assay development by providing a novel approach to screen G-protein coupled receptors (GPCR) and other key drug target classes, as well as providing a methodology to convert live cell assays into ready-to-use consumable products. Sentigen will become a part of Invitrogen's Discovery Sciences Business based in Madison, Wis.

Tango(TM) assay technology provides a universal assay system for GPCR targets, the most screened target class in drug discovery. The Tango(TM) assay platform also has utility in measuring protein-protein interactions in living cells, which can be an important way to determine the function of a protein of interest. Sentigen's Assay Ready Cells(TM) technology is designed to improve the quality and consistency of cellular assays used in drug screening and reduce the need of our clients to engage in costly ongoing cell culture operations to support cell-based drug discovery, effectively uncoupling the process of cell production from drug screening.

"Adding Sentigen's capabilities to our drug discovery platform gives researchers an even broader array of solutions for GPCR screening, profiling and other cellular studies," explained Nick Ecos, Vice President and General Manager of Invitrogen's Discovery Sciences business.

"The synergy created by combining Invitrogen's cell and molecular biology products with Sentigen's cell-based technologies and custom services enhances our strategic commitment to scientists engaged in cell-based drug discovery by offering our clients comprehensive solutions and support," said Tom Livelli, Sentigen's President and CEO.

The transaction is subject to customary closing conditions, including the approval of Sentigen's stockholders and is expected to close in the fourth quarter. Invitrogen does not expect this acquisition to have a material affect on its financials in fiscal year 2006 or decelerate the progress of its share repurchase program previously announced on August 3, 2006.

"We are committed to deploying our capital for purchases of targeted acquisitions, such as Sentigen, as well as executing upon our share repurchase program," said David Hoffmeister, Invitrogen's Chief Financial Officer. "As we indicated on our earnings call, we plan to use a sizable portion of the authorization in the near term and we have already made progress towards this goal."

About Invitrogen Corporation

Invitrogen Corporation (Nasdaq:IVGN) provides products and services that support academic and government research institutions and pharmaceutical and biotech companies worldwide in their efforts to improve the human condition. The company provides essential life science technologies for disease research, drug discovery and commercial bioproduction. Invitrogen's own research and development efforts are focused on breakthrough innovation in all major areas of biological discovery, including functional genomics, proteomics and cell biology -- placing Invitrogen's products in nearly every major laboratory in the world. Founded in 1987, Invitrogen is headquartered in Carlsbad, Calif., and conducts business in more than 70 countries around the world. The company globally employs approximately 4,800 professionals and had revenues of more than $1.2 billion in 2005. For more information, visit

About Sentigen Holding Corp.

Sentigen Holding Corp. conducts business through two wholly-owned operating subsidiaries: Sentigen Biosciences, Inc. ("Sentigen Biosciences") and Cell & Molecular Technologies, Inc. ("CMT"). CMT provides contract research and development services to companies engaged in the drug discovery process in the following areas: molecular and cell biology, gene expression and protein biochemistry, bio-processing, high throughput screening support services, mouse genetics and cell-based GPCR selectivity profiling. Sentigen Biosciences has been primarily engaged in the development and commercialization of novel bioassay systems that elucidate the underlying biology of protein-protein interactions. Sentigen Biosciences has initially targeted its Tango(TM) Assay System to address the functionalization of G protein-coupled receptors (GPCRs) for pharmaceutical drug discovery and development. For more information on our companies, please visit their respective websites: and

Safe Harbor Statement

Certain statements contained in this press release are considered "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, and it is Invitrogen's intent that such statements be protected by the safe harbor created thereby. Forward-looking statements include, but are not limited to: 1) Sentigen's Tango Assay System and division arrested Assay Ready Cells will improve Invitrogen's position in assay development for GPCRs; and 2) the Sentigen business will become a part of Invitrogen's Discovery Sciences Group. Potential risks and uncertainties include, but are not limited to, the risks that: a) Sentigen's technologies may not have a significant impact on Invitrogen's assay development activities; and b) Invitrogen may choose to align the business in an area outside the Discovery Sciences group., as well as other risks and uncertainties detailed from time to time in Invitrogen's Securities and Exchange Commission filings.
COPYRIGHT 2006 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:Sep 1, 2006
Previous Article:KB Home to Broadcast Presentation at the Credit Suisse 2006 Homebuilding Symposium.
Next Article:Nutralogix to Release New Product Line Expected to Produce Major Impact on Nutraceutical Market after Labor Day.

Related Articles
Invitrogen to Acquire Products and Technology Rights of PanVera LLC from Vertex Pharmaceuticals; Transaction Expected to be Accretive to Invitrogen's...
Chemical engineering.
Invitrogen picks up two new businesses.
PathAlert Infectious-Agent Detection System.
Invitrogen Unveils New Innovations at American Association for Cancer Research (AACR) Conference, Recognized by Peers at Life Science Industry Awards.
Invitrogen and Cellartis Collaborate to Create hESC Multi-Lineage Reporter Lines.
Sentigen Signs Definitive Merger Agreement with Invitrogen Corporation; Sentigen Stockholders to Receive $3.37 Per Share in Cash.
Sentigen Holding Corp. Stockholders Approve Merger with Invitrogen Corporation.
Invitrogen Features New Scientific Online Resources at American Society for Cell Biology (ASCB) Meeting.
Invitrogen and Emiliem Sign Major Kinase Screening Agreement.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters